Brain NAD in Alzheimer's Disease

The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.

Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Alzheimer Disease (AD) Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

FAU Clinical Research Unit

Boca Raton, Florida, 33431, United States

Location status: Recruiting

Location contact

Judyta Kociolek

CONTACT

[email protected]

5612974963

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
Age 65 to 80 included.
People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.

Exclusion criteria

Under the age of 65 or over the age of 80.
Advanced dementia such that the person would require sedation for undergoing an MRI scan.
Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
Having a history of seizures.
Working at night.
Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
People with no AD: MoCA test result lower than 26.

Treatment and study plan

Primary outcomes

Brain NAD

Time frame: At enrollment and 8 months after enrollment

NAD levels measured by 1H-MRS

Study contacts

Contact information is provided by the study sponsor or research team.

FAU Clinical Research Unit Central Contact

CONTACT

[email protected]

561-235-4467

Sponsors and collaborators

Lead sponsor

Florida Atlantic University

Other

Registry information

Official study title

Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS

Acronym: ALZNAD

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 17, 2025
Registry last updated: Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting